Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction

BACKGROUND: Androgen ablation is the first-line therapy for patients with metastatic prostate cancer (CaP). However, castration resistance will eventually emerge. In the present study, we have investigated the role of bone morphogenetic protein-6 (BMP-6) in the development of castration-resistant pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, G T, Kang, D I, Ha, Y-S, Jung, Y S, Chung, J, Min, K, Kim, T H, Moon, K H, Chung, J M, Lee, D H, Kim, W-J, Kim, I Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960605/
https://www.ncbi.nlm.nih.gov/pubmed/24518599
http://dx.doi.org/10.1038/bjc.2014.23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960605/
https://www.ncbi.nlm.nih.gov/pubmed/24518599
http://dx.doi.org/10.1038/bjc.2014.23

Ejemplares similares